EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumors

Hong Yan, April W Mao, Dan Li, Guangbo Fu, Manuel Jesús Pérez-Baena, Alejandro Jiménez-Navas, Dawei Wang, Ryan Hong, Weidong Cai, Jesus Pérez-Losada, Kuang-Yu Jen, Sen Wang und 9 weitere

Cancer Letters · 2026-06 · 647 · 218447

DOI: 10.1016/j.canlet.2026.218447 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Letters, 2026-06. Verfasst von Hong Yan und 20 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medicine Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Androgen Antagonists, Artificial Intelligence, Biomarkers, Tumor, Prostatic Neoplasms. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Energy, National Institutes of Health National Cancer Institute, US Office of Congressionally Directed Medical Research Programs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is imperative to identify patients with prostate cancer (PCa) who will not benefit from androgen receptor signaling inhibitors and to improve their clinical outcomes. Using artificial intelligence (AI), in this multicenter cohort study of 623 PCa patients, we identified 13 cellular morphometric biomarkers (CMBs), as a New Approach Methodology (NAM), from whole slide images of needle biopsies in clinical trial specimens (NCT02430480, n = 37) that accurately predicted response to neoadjuvant androgen deprivation therapy (NADT) plus enzalutamide (AUC: 0.981, 95% CI [0.979, 0.983]). Importantly, the 13-CMB model stratified PCa patients into responders and non-responders after NADT across two independent hospital cohorts. In one cohort (n = 122), the model identified groups with significantly different pathologic complete response (pCR) (p = 0.0005) and biochemical recurrence-free survival (BCRFS) (p = 0.024). In the second cohort (n = 60), the model similarly distinguished patients with significantly different BCRFS (p = 0.031). The 13-CMB model also stratified PCa patients in the TCGA-PRAD cohort (n = 396) with distinct progression-free survival (p = 0.0017). Importantly, across hospital cohorts and the TCGA-PRAD cohort, the 13-CMB model demonstrated significant and independent clinical value after adjustment for established clinical factors and commonly used genomic biomarkers, including Decipher and Oncotype DX. Furthermore, CMBs accurately predicted the molecular differences between stratified patient groups and the potential benefit from mTOR inhibitors in non-responders, which were validated through IHC staining and patient-derived organoids (n = 8), respectively. Overall, our AI-powered CMB model, relying only on routine needle biopsy specimens, could potentially serve as a robust solution for precision management of PCa patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsArtificial IntelligenceBiomarkers, TumorProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantTOR Serine-Threonine KinasesAgedHumansMaleMiddle AgedBenzamidesBiopsy, NeedleDrug Resistance, NeoplasmNeoadjuvant TherapyNitrilesPhenylthiohydantoinClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

Artificial intelligenceCellular morphometric biomarkerNeoadjuvant androgen deprivation therapyNew approach methodology (NAM)Prostate cancermTOR inhibition

Substanzen

Androgen AntagonistsBenzamidesBiomarkers, TumorenzalutamideMTOR protein, humanNitrilesPhenylthiohydantoinTOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • Laboratory Medicine Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA, United States; Berkeley Biomedical Data Science Center, Lawrence Berkeley National Laboratory, Berkeley, CA, United State…
  • Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Department of Urology, The Affiliated Huaian No.1 People's Hospital, Nanjing Medical University, Huaian, Jiangsu, China.
  • Instituto de Biología Molecular y Celular Del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, 37007, Spain; Instituto de Investigación Biosanitaria de Salamanca (IBSAL), Salamanca, 37007, Spain.
  • School of Computer Science, The University of Sydney, Sydney, NSW, 2006, Australia.

Förderung

  • U.S. Department of Energy
  • National Institutes of Health National Cancer Institute
  • US Office of Congressionally Directed Medical Research Programs
  • National Institutes of Health
  • University of California
  • U.S. Department of Defense

Zitieren

APA

Yan, H., Mao, A. W., Li, D., Fu, G., Pérez-Baena, M. J., Jiménez-Navas, A., Wang, D., Hong, R., Cai, W., Pérez-Losada, J., Jen, K. Y., Wang, S., Peng, S., Barcellos-Hoff, M. H., Shen, H., Lin, N., Mao, J. H., Fu, Y., Iczkowski, K. A., …, & Chang, H. (2026). AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumors. Cancer Letters, 647, 218447. https://doi.org/10.1016/j.canlet.2026.218447

Vancouver

Yan H, Mao AW, Li D, Fu G, Pérez-Baena MJ, Jiménez-Navas A, et al. AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumors. Cancer Letters. 2026;647:218447. doi:10.1016/j.canlet.2026.218447

BibTeX
@article{Yan2026,
  author = {Yan, Hong and Mao, April W and Li, Dan and Fu, Guangbo and Pérez-Baena, Manuel Jesús and Jiménez-Navas, Alejandro and Wang, Dawei and Hong, Ryan and Cai, Weidong and Pérez-Losada, Jesus and Jen, Kuang-Yu and Wang, Sen and Peng, Shan and Barcellos-Hoff, Mary Helen and Shen, Han and Lin, Ning and Mao, Jian-Hua and Fu, Yao and Iczkowski, Kenneth A and Gulati, Shuchi and Chang, Hang},
  title = {AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumors},
  journal = {Cancer Letters},
  year = {2026},
  volume = {647},
  pages = {218447},
  doi = {10.1016/j.canlet.2026.218447}
}
Kostenlos starten →